Yazar "Altundag, Kadri" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.(Amer Soc Clinical Oncology, 2015) Benekli, Mustafa; Altundag, Kadri; Dumanli, Esra; Isikdogan, Abdurrahman; Karaoglu, Aziz; Tekin, Salim Basol; Oksuzoglu, Berna[Abstract Not Availabe]Öğe Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.(Amer Soc Clinical Oncology, 2015) Benekli, Mustafa; Altundag, Kadri; Dumanli, Esra; Isikdogan, Abdurrahman; Karaoglu, Aziz; Tekin, Salim Basol; Oksuzoglu, Berna[Abstract Not Availabe]Öğe Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases(Sage Publications Ltd, 2014) Artac, Mehmet; Koral, Lokman; Toy, Hatice; Guler, Tunc; Boruban, Melih C.; Altundag, KadriPresentation with bone marrow metastasis at diagnosis is a rare event in breast carcinoma. Here, we report a rare presentation of metastatic breast cancer patient with bone marrow metastases, who was successfully treated with trastuzumab combined chemotherapy. The regimens initially applied for bone marrow metastasis were docetaxel/adriamycin, gemcitabine/vinorelbine, epirubicin/cyclophosphamide, capecitabine, docetaxel, gemcitabine, and paclitaxel. But, the best response to these regimens was not satisfactory. Our patient was completely treated with etoposide-cisplatin and trastuzumab combination. She is still on remission after five years of metastatic breast cancer diagnosis using letrozole and trastuzumab without complication. Physicians should be careful in treating bone marrow metastases in breast cancer, since patients can show improved marrow function after chemotherapy and long-lasting survival is possible.Öğe Evaluating The Clinicopathologic Characteristics and Survival Outcome of Breast Cancer Patients with Isolated Brain Metastases after Adjuvant Treatment or at Initial Diagnosis(Modestum Ltd, 2012) Boruban, Cem; Gulyer, Huseyin; Altundag, Kadri; Artac, Mehmet; Guler, Tunc; Cengiz, MustafaCNS metastases usually appears late in the progression of metastatic breast cancer. Classical approach is evaluating and treating them when symptoms become evident. We evaluated the survival and described clinicopathologic characteristics of patients in whom the brain metastases after adjuvant treatment or at initial diagnosis are the first and the only side. Authors retrospectively evaluated about 3600 patients with breast cancer treated in two university hospitals. In those 31 patients with first and only metastases to brain and no other metastases were evaluated. ER, PR, cerbB2 status T, N stage, grade, adjuvant taxane, trastuzumab, hormonal treatment, trastuzumab and platine use after brain metastases didn't effect the survival. Surgery and WBRT may be more effective in cerbB2 negative patients, WBRT in cerbB2 positive ones. (p=0.06). The survival outcome may be better in pre and perimenouposal women. The mOS of pre and perimenopausal, postmenopausal women were 17.7 months and 10.3 months respectively (p=0.06) and lapatinib may affect the mOS of patients with isolated brain metastases. Some prognostic factor may help us to foresee which group may benefit more from which treatment modality. The need for studies with larger groups of patients is obvious.Öğe Turkish Breast Cancer Registry: A multicenter epidemiologic study(Lippincott Williams & Wilkins, 2014) Coskun, Ugur; Gumus, Mahmut; Uncu, Dogan; Ozkan, Metin; Cicin, Irfan; Altundag, Kadri; Elklran, Tamer[Abstract Not Availabe]Öğe Turkish Breast Cancer Registry: A multicenter epidemiologic study(Lippincott Williams & Wilkins, 2014) Coskun, Ugur; Gumus, Mahmut; Uncu, Dogan; Ozkan, Metin; Cicin, Irfan; Altundag, Kadri; Elklran, Tamer[Abstract Not Availabe]
